EMA Fees: Parliamentary Committee Insists On Full Transparency & Sufficient Funding
Executive Summary
The ENVI committee says the regulatory work done by national regulators on behalf of the European Medicines Agency must be properly remunerated to ensure “world-class pharmaceutical supervision."
You may also be interested in...
EMA Fee Proposals Pass Another Legislative Milestone
Agreement on a new, more streamlined fee structure for the European regulator could be reached by the end of this year.
Medicines For Europe Urges EU To Implement ‘Fair’ Approach To EMA Fees
Medicines for Europe has urged the EU to reject European Council proposals to increase regulatory and pharmacovigilance fees, as part of an effort to simplify the fee structure at the European Medicines Agency.
EU Ministers Back Greater Role For Member States In Updating EMA Fees
The Council of the EU has broadly accepted the European Commission’s proposal for a new, cost-based fee and remuneration system, but has suggested giving the European Medicines Agency’s management board – and hence the member states – a bigger role in future fee changes.